Advisory committees comprised of content experts, practitioners, and patient advocates from across Texas assist CPRIT and its Oversight Committee by focusing upon particular issues critical to CPRIT’s efforts. While some CPRIT advisory committees are created by statute, the Oversight Committee may create additional committees of experts to provide advice on specific cancer-related topics. With the input of its advisory committees, the Oversight Committee is better-equipped to make the informed decisions about CPRIT’s programs and policies.
Looking for CPRIT’s peer review committees? Click here
The University Advisory Committee (UAC) advises the Oversight Committee about the role of higher education in cancer research. The nine members of the UAC include representatives of all of Texas’ public university systems and private research universities.
The Advisory Committee on Childhood Cancers (ACCC) advises the Oversight Committee on issues surrounding childhood cancer. The Oversight Committee is responsible for appointing members to the committee. The ACCC collects current information regarding innovative research on the prevention, control and cure of childhood cancers, and current information regarding treatment programs designed to prevent and control cancer.
The Advisory Committee on Product Development provides targeted advice to the Oversight Committee concerning the agency’s product development program. Examples of issues include:
- General contractual revenue sharing provisions that provide a fair return for the State of Texas while not discouraging follow-on funding from other sources;
- Appropriate portfolio mix of product development awards by stage of company and size of award; and
- Strategies to expand and encourage relocation of high quality companies to Texas.
The primary purpose of the CTAC is to advise the Oversight Committee on important issues of the clinical trials. The CTAC shall give their expert opinion on the impact of current CPRIT mechanisms supporting clinical trials; give advice on opportunities to increase CPRIT’s impact on translating basic discoveries to clinical trials; and advise on mechanisms that would address barriers to patient enrollment in therapeutic clinical trials.